Concepts (86)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
| Tuberculosis, Meningeal | 2 | 2018 | 100 | 0.80 | Why? |
| Genetic Variation | 1 | 2021 | 3919 | 0.33 | Why? |
| Patient Selection | 1 | 2020 | 4560 | 0.30 | Why? |
| Randomized Controlled Trials as Topic | 3 | 2021 | 10649 | 0.28 | Why? |
| Hospitals | 2 | 2021 | 11793 | 0.24 | Why? |
| Clinical Trials as Topic | 1 | 2021 | 7330 | 0.23 | Why? |
| Host-Pathogen Interactions | 1 | 2021 | 11041 | 0.21 | Why? |
| Mutation | 1 | 2021 | 12376 | 0.21 | Why? |
| Genome, Viral | 2 | 2021 | 13157 | 0.20 | Why? |
| Biomedical Research | 1 | 2020 | 5270 | 0.20 | Why? |
| Models, Theoretical | 1 | 2018 | 6659 | 0.19 | Why? |
| Coinfection | 2 | 2018 | 6820 | 0.18 | Why? |
| Eligibility Determination | 1 | 2020 | 255 | 0.18 | Why? |
| Leukocytosis | 1 | 2018 | 280 | 0.15 | Why? |
| Disease Outbreaks | 2 | 2021 | 27595 | 0.13 | Why? |
| Immunization Schedule | 1 | 2021 | 1305 | 0.13 | Why? |
| United Kingdom | 4 | 2021 | 18046 | 0.13 | Why? |
| Base Sequence | 1 | 2021 | 3581 | 0.13 | Why? |
| Immunization, Secondary | 1 | 2021 | 1649 | 0.12 | Why? |
| HIV Infections | 2 | 2018 | 11620 | 0.12 | Why? |
| Vietnam | 1 | 2018 | 1665 | 0.12 | Why? |
| Nomograms | 1 | 2018 | 790 | 0.11 | Why? |
| Pandemics | 6 | 2021 | 389249 | 0.11 | Why? |
| Observational Studies as Topic | 1 | 2018 | 1887 | 0.10 | Why? |
| Mycobacterium tuberculosis | 1 | 2018 | 1164 | 0.09 | Why? |
| State Medicine | 1 | 2021 | 2847 | 0.08 | Why? |
| World Health Organization | 1 | 2020 | 4213 | 0.08 | Why? |
| Immunity, Humoral | 1 | 2020 | 4849 | 0.08 | Why? |
| ROC Curve | 1 | 2018 | 6024 | 0.07 | Why? |
| Phylogeny | 2 | 2021 | 13341 | 0.07 | Why? |
| Proportional Hazards Models | 1 | 2018 | 6543 | 0.07 | Why? |
| Asymptomatic Infections | 2 | 2021 | 7218 | 0.07 | Why? |
| Pneumonia, Viral | 4 | 2020 | 243684 | 0.07 | Why? |
| Nursing Homes | 1 | 2021 | 4155 | 0.07 | Why? |
| Coronavirus Infections | 4 | 2020 | 253789 | 0.06 | Why? |
| Adenosine Monophosphate | 1 | 2020 | 5652 | 0.06 | Why? |
| Alanine | 1 | 2020 | 5687 | 0.06 | Why? |
| Clinical Laboratory Techniques | 2 | 2020 | 23402 | 0.06 | Why? |
| Humans | 14 | 2021 | 930598 | 0.06 | Why? |
| Prospective Studies | 3 | 2021 | 43301 | 0.05 | Why? |
| Middle Aged | 6 | 2021 | 270681 | 0.05 | Why? |
| Registries | 1 | 2020 | 12327 | 0.05 | Why? |
| Male | 8 | 2021 | 367725 | 0.05 | Why? |
| Sequence Analysis | 1 | 2021 | 496 | 0.05 | Why? |
| Female | 7 | 2021 | 380317 | 0.05 | Why? |
| England | 2 | 2021 | 5116 | 0.05 | Why? |
| Time Factors | 2 | 2021 | 31397 | 0.04 | Why? |
| Cross Infection | 1 | 2020 | 8675 | 0.04 | Why? |
| Polymorphism, Single Nucleotide | 2 | 2021 | 3607 | 0.04 | Why? |
| Single-Blind Method | 1 | 2020 | 1283 | 0.04 | Why? |
| Health Services Accessibility | 1 | 2020 | 10697 | 0.04 | Why? |
| Age Factors | 1 | 2018 | 21039 | 0.04 | Why? |
| Cerebrospinal Fluid | 1 | 2018 | 234 | 0.04 | Why? |
| Infection Control | 2 | 2020 | 23131 | 0.03 | Why? |
| Prognosis | 1 | 2018 | 32490 | 0.03 | Why? |
| Public Health | 1 | 2020 | 16359 | 0.03 | Why? |
| Infectious Disease Transmission, Professional-to-Patient | 1 | 2021 | 1316 | 0.03 | Why? |
| Betacoronavirus | 4 | 2020 | 204454 | 0.03 | Why? |
| Adult | 5 | 2021 | 244371 | 0.03 | Why? |
| South Africa | 1 | 2020 | 3326 | 0.03 | Why? |
| Health Personnel | 1 | 2020 | 29646 | 0.02 | Why? |
| Severity of Illness Index | 1 | 2018 | 48226 | 0.02 | Why? |
| Retrospective Studies | 1 | 2021 | 105322 | 0.02 | Why? |
| Double-Blind Method | 1 | 2020 | 5988 | 0.02 | Why? |
| Whole Genome Sequencing | 1 | 2020 | 3239 | 0.02 | Why? |
| Hospitalization | 1 | 2020 | 54280 | 0.02 | Why? |
| Genomics | 1 | 2021 | 3118 | 0.02 | Why? |
| Lymphocyte Count | 1 | 2020 | 4758 | 0.02 | Why? |
| Hospitals, University | 1 | 2020 | 4173 | 0.02 | Why? |
| Antibody Formation | 1 | 2021 | 4038 | 0.02 | Why? |
| Adolescent | 3 | 2021 | 86841 | 0.02 | Why? |
| Young Adult | 3 | 2021 | 93724 | 0.02 | Why? |
| Polymerase Chain Reaction | 1 | 2020 | 6740 | 0.02 | Why? |
| Patient Safety | 1 | 2020 | 4885 | 0.02 | Why? |
| Treatment Outcome | 2 | 2020 | 51732 | 0.02 | Why? |
| Fever | 1 | 2020 | 7795 | 0.02 | Why? |
| Brazil | 1 | 2020 | 12582 | 0.02 | Why? |
| Real-Time Polymerase Chain Reaction | 1 | 2020 | 11367 | 0.01 | Why? |
| Aged, 80 and over | 2 | 2021 | 88759 | 0.01 | Why? |
| Aged | 3 | 2021 | 215776 | 0.01 | Why? |
| Infant, Newborn | 1 | 2020 | 23105 | 0.01 | Why? |
| Infectious Disease Transmission, Patient-to-Professional | 1 | 2021 | 9706 | 0.01 | Why? |
| Infant | 1 | 2020 | 30274 | 0.01 | Why? |
| Child, Preschool | 1 | 2020 | 36283 | 0.01 | Why? |
| Child | 1 | 2020 | 70012 | 0.01 | Why? |
| Antiviral Agents | 1 | 2020 | 41703 | 0.01 | Why? |